Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.

Author: , KuboY, NakagawaH, OotakiK, YamasakiK

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Brodalumab, a monoclonal antibody targeting IL-17RA, was found to be effective and safe in treating Japanese patients with generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE) in this open-label phase III study. After 52 weeks, 11 out of 12 patients with GPP and 18 out of 18 patients with PsE achieved remission or improvement, with the most common side effect being nasopharyngitis (33.3%).
Paper Details　
Original Abstract of the Article :
BACKGROUND: A T-helper (Th) cell subset Th17 preferentially produces interleukin (IL)-17 and plays a pivotal role in the pathogenesis of psoriasis. However, the pathological roles of IL-17 cascades in generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE) have not been well establishe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/bjd.14702

データ提供：米国国立医学図書館（NLM）

A New Weapon Against Psoriasis: The Efficacy of Brodalumab

Psoriasis, a chronic skin condition, can feel like a relentless desert storm, causing discomfort and affecting quality of life. This study explores the effectiveness of brodalumab, a new treatment option for generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE). The authors demonstrate the promising results of brodalumab in achieving significant symptom improvement and remission, offering a potential oasis in the desert of psoriasis treatment.

Fighting the Storm: A New Treatment for Psoriasis

This research showcases the potential of brodalumab as a valuable tool for treating severe forms of psoriasis. The study reveals that brodalumab effectively reduces symptoms, leading to significant improvement and even remission in many patients. This research is like discovering a new source of water in a desert, offering a much-needed lifeline for individuals battling this challenging skin condition.

Hope for a Clearer Future

This study provides hope for individuals living with GPP and PsE, suggesting that brodalumab could significantly improve their quality of life. The study's results highlight the promising future of targeted therapies for psoriasis, offering a potential pathway toward long-term symptom relief and a clearer skin.

Dr. Camel's Conclusion

This research offers a beacon of hope for individuals battling psoriasis. The study reveals the effectiveness of brodalumab in achieving significant symptom improvement and remission, offering a potential oasis in the desert of psoriasis treatment. This study highlights the importance of continued research and development of targeted therapies to address the needs of those living with chronic skin conditions, offering a path toward a brighter and healthier future.
Date :
  1. Date Completed 2017-10-11
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

27106510

DOI: Digital Object Identifier

10.1111/bjd.14702

Related Literature

Article Analysis
・Effects of brodalumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.